Clinical Review of Atenolol as an Antihypertensive by Dr F J Zacharias (Clatterbridge Hospital, Merseyside) The origin of atenolol is to be found in a decision of the Pharmaceuticals Division of ICI in about 1968 to produce a beta-adrenoceptor antagonist which would (1) be as potent as propranolol, (2) have no partial agonist or intrinsic sympathomimetic activity, (3) have no membrane stabilizing activity, (4) be as cardioselective as practolol, (5) have a relatively long chemical half-life, and (6) be water-soluble with little brain penetration. Of the numerous substances examined, atenolol came nearest to the desired profile. In 1968 there were only two beta-adrenoceptor antagonists available for general use and both were nonselective. One cardioselective beta blocker, practolol, was at a fairly advanced stage of development, but had not yet been launched, and two other nonselective beta blockers, oxprenolol and sotalol, were about to be launched. Since then a great many hospital and general practitioner investigators, particularly in the United Kingdom, have contributed in their various ways to the present knowledge of atenolol, and perhaps the time is ripe to see how atenolol measures up to the expectations of its creators.
Is atenolol effective? It is hardly necessary to answer that question because there is a wealth of evidence, not just a few odd papers, testifying to its antihypertensive effect. Previous beta blockers were looked at primarily in terms of their effect on angina or cardiac arrhythmias, and only later did they become acknowledged as effective antihypertensives; atenolol was primarily designed as an antihypertensive agent. Dr Hansson and his Swedish colleagues and Lund Johanssen from Norway had faith in beta blockers at a time when Prichard, Gillam and a few others of us were struggling against a tide of conservative scepticism. Hansson (1977) showed clearly that there was a fall of approximately 25 mmHg systolic and 15 mmHg diastolic with an optimum dose of 200 to 300 mg atenolol per day which was relatively free from side effects, and marked a significant improvement against placebo. The hypotensive effect was comparable to that seen with propranolol within the dose iange used. Now, in much longer multicentre trials equally good results have been forthcoming with equal freedom from adverse effects. Professor Dollery's group confirms (p 00) that atenolol is an effective antihypertensive drug, which has a relatively flat dose-response curve, and that in relatively high doses (up to 900 mg/ day) there is a gratifying freedom from adverse effects. Similar views about its effectiveness have come from Professor Amery and his colleagues in Belgium, who found no clear correlation between the antihypertensive effect of atenolol and its effect on cardiac output, plasma renin and a number of other factors.
The meticulously controlled studies of Petrie and his colleagues from Aberdeen (1977) convincingly confirmed the value of atenolol in quite small doses, and I say that as somebody who really did not initially believe in the small dose concept, but I have clearly had to change my view utterly and completely. In addition, atenolol has been compared with other antihypertensive drugs, particularly methyldopa, because this is still the most commonly used remedy in the treatment of hypertension. Atenolol has been found to be equally effective, and when larger doses are used, methyldopa has a much higher incidence of adverse effects. Dr Petrie and Dr Scott have confirmed this in studies that were similarly designed and had similar results. From all these data there can be no doubt that atenolol is effective, like most other beta blockers.
The main advantage of once-daily dosage lies in greater patient compliance, although the crucial improvement probably comes when the dose is reduced from three times a day to twice a day. We should not be too obsessed with the current fashion of once-daily dosage. This may be a valuable property in a drug with only a small dose range, but with drugs such as propranolol or sotalol, which have large dose ranges, it is a very different matter. It would not be reasonable, for example, to expect patients to take six of the 160 mg tablets of propranolol or oxprenolol in a single dose. If a combined regime of a beta blocker and a diuretic is being given and the dose of the beta blocker is a small one, then clearly a once-daily regime is preferable. If another drug, e.g. methyldopa, prazosin or hydrallazine is being added then it does not seem to be quite so relevant to insist on a once-daily dose of the beta blocker. The problem of compliance is one that everybody has rightly stressed as being very important, and it is one of the weakest aspects of the attack on hypertension. Our experience over the last twelve years, when for a great deal of the time 250 mg tablets of propranolol and 200 mg tablets of practolol were being used, was that even in an apparently well-motivated group of patients who received all their drugs in exact monthly amounts from the hospital pharmacy, the compliance rate was poor. The chemical half-life of atenolol is about 7 to 9 hours but we must beware of equating the chemical and biological halflives. It is unquestionably possible to give other beta blockers on a once-daily dosage and this regime seems just as effective in the long-term treatment of hypertension. While the great majority of people seem to get on perfectly well on 100 mg/day of atenolol, there are a small number, in my experience, who do require larger doses, up to 400 mg a day, and there are a very few whose blood pressure is not controlled except on very large doses. For example, a patient who had been on 1 g/day together with other drugs, had the dose of atenolol reduced from 1 g/day to 900 mg and then 800 mg and the blood pressure went out of control, and could only be recontrolled when the dose was increased to 900 mg/day. In this patient there seemed to be a very delicate balance where a slight reduction or increase in the dose makes a lot of difference. She is well-motivated, intelligent, and has an extremely good GP, so the conditions were quite favourable for accurate control. She has tried every other drug and has never been controlled at all over a period of ten years. Before coming to see me, she had tried bethanidine, debrisoquine, guanethidine, methyldopa, and clonidine, and her diastolic pressure never went below 1 20mmHg. She is one of the people who needs a large dose, even of atenolol, but these people are very small in number. Likewise, 1 % of patients are managing regularly on 50 mg/day.
Atenolol is very valuable in combination with other drugs such as hydrallazine, prazosin and diuretics. One of the characteristics of atenolol is the absence of membrane stabilizing activity and in this respect it differs from propranolol but resembles sotalol. At one time it appeared that this property might be associated with myocardial depression, but this is quite irrelevant in the clinical situation. The possession of MSA might be undesirable in the diabetic patient, and perhaps the combination of cardioselectivity and no MSA might be useful in terms of not impairing the recovery of blood glucose in hypoglycmmia.
If this is confirmed, then quite clearly atenolol would be preferable when a beta blocker is required in the diabetic. With beta blockers in general, covering experience with 1200 people over 12 years, quite a number of non-insulin dependent diabetics have been looked at and they have been put on propranolol and latterly atenolol without any trouble.
Animal work confirms that atenolol does not possess intrinsic sympathomimetic activity and it is accepted that this property contributes nothing to the control of blood pressure; indeed it appears to be a definite disadvantage when large doses of beta blockers are given. There is no doubt from experience of practolol, that when very large doses (21 to 4 g) were given it was found that many patients were poorly controlled. When practolol was withdrawn over a period of a month or two the blood pressure went up in about one third of 20 patients, although other drugs were continued, in a third it remained the same and in a third it went down. The fact that the blood pressure either stayed the same or went down when practolol was withdrawn may have something to do with the amount of partial agonist activity. There have been a number of reports, especially from the Southern Hemisphere, of this phenomenon with pindolol and many people claim that there is an upper dosage level of pindolol, beyond which it is quite useless to go. With high-dose propranolol patients, when the dose was reduced, the blood pressure went out of control, and had to be restored to large levels such as 1.5 or 2.0 g/day.
The two most important characteristics of atenolol in clinical terms are cardioselectivity and the narrow dose range. Turner and his colleagues regard atenolol as half-way in selectivity between propranolol and practolol, but Vilsvik clearly believes it is equal to practolol. Although Benson (p 48) did not actually compare it with practolol, his work showed that the selective drugs are superior to the nonselective in patients prone to bronchospasm. Perhaps his division of responders and nonresponders might in the future cause a little confusion because they might reallyrepresent different phases in the same individual. One practical implication of this is that if the greater reversibility of bronchospasm when using a selective beta blocker is really found to be true, then clearly this is very important. A very large number of patients are now on beta blockers and inevitably a few people have become wheezy. On clinical grounds it appears that atenolol is as selective as practolol, but all patients should be warned when they are on any kind of beta blocker, that if they become wheezy they must immediately get in touch with their GP and be prepared, if on a nonselective drug, to stop taking it at once. However, patients on atenolol in a small dose of 100 mg/day may be given a supply of salbutamol so that they may use it promptly if they get into trouble. If they use a beta2 stimulant very quickly, and then send for their doctor, they usually get away with an episode of bronchospasm without stopping atenolol, which was not the case with propranolol or any other nonselective beta blockers. Acebutolol is not in any way comparable with atenolol in terms of cardioselectivity, no matter what the animal experiments may show, and it is important to realize that the situation in the field does sometimes differ from that in the laboratory.
When assessing the place of a new beta blocker, in addition to the short-term, sophisticated, detailed studies, it has to be looked at on a longterm basis in a large number of patients. Anyone who doubts this has only to consider the history Experience at Clatterbridge with atenolol in hypertension goes back more than four years, and involves about 550 patients. We are convinced that atenolol is a very effective remedy indeed. With atenolol alone, an initial average group blood pressure of 180/113 mmHg fell at the last visit to 147/91 mmHg. In the second group, having atenolol plus diuretic, there is the same satisfactory fall, and an even more satisfactory fall in the group receiving diuretic, atenolol and a vasodilator, mostly prazosin or hydrallazine. There is a variability in response from patient to patient and in general the response to propranolol and sotalol is dose-dependent. This may not be quite the same in beta blockers which possess ISA but in our experience with very high doses of propranolol when these were reduced the blood pressure went out of control. Some of these people can achieve good control on these very high doses, and control can be sustained for years. General physicians rarely need to use these doses and there is a very strong case to be made out for using combinations of drugs, provided they are not too complex. Renal physicians are among those who do appreciate the need for very large doses sometimes, and they have, in general, been somewhat bolder in their use of drugs such as propranolol.
When atenolol was first used it was assumed on the evidence of what was known about propranolol, that it was a titratable drug with a doseresponse curve similar to propranolol. With hindsight, this was clearly a mistake, but the same principles of treatment were adopted. If at the first visit the diastolic pressure average of four or five readings was below 90 mmHg, the dose was unchanged, and if it was above 90 mmHg the dose was increased. That is what we tried to do, and so the dose was gradually built in a large number of people over a period of two years or so. Then it was realized that all was not well. About this time we began to hear of the experience of Petrie and others that the small dose was really most satisfactory for most people, and looked at computer results. We had steadily raised the dosage and included a number of people on 1 g/ day who were certainly no better off, and it seemed logical to make a systematic and open reduction.
We therefore decided to reduce by 200 mg/ fortnight. This was gradually effected over a period of about 15 months and Fig 1 indicates the kind of change of dose which was made in these people. About 77 patients were on 1 g/day and there were one or two on much larger doses, but over this period the dose was gradually reduced until most were taking 600 mg and quite a number substantially less. The average of the highest recorded dose in this group of about 94 patients was just over 1000 mg/day, and we have since gone down much further, to around 600 mg/ day. At the end of that 15-month period there was a satisfactory control of blood pressuresystolic 152 mmHg, diastolic 93 mmHg, pulse 60/min at the beginning on the higher dose, and systolic 143 mmHg, diastolic 88 mmHg, pulse rate 61 on the much lower dose. A small subgroup had the mean dose reduced from 1000 mg to about 330 mg/day with the same satisfactory maintenance of control and no obvious change in the pulse rate.
Next it was decided to look at the question of dosage a little more accurately, and 60 of the patients who were on 600 mg/day were given randomly and in a double-blind manner, three alternative scheduleseither 600, 200 or 100 mg/ day. For three months they were on each schedule and there has been little if any escape from control except perhaps in very few patients. All this confirms Petrie's work, although there is still a small residue of patients who do seem to need high doses.
The relationship between the untreated diastolic pressure and the final control is shown in Table 1 . Four out of 53 patients showed no improvement at all, and one showed a marginally higher blood pressure than before. In 7 patients the response was disappointing and indifferent, but in 41 out of 53 it was very good. In the second group (Table 2) , consisting of people on atenolol plus a diuretic (5 mg of bendrofluazide daily) only 2 out of 127 of them showed absolutely no response at all. The third group (Table 3) were the difficult cases who had atenolol, diuretic and other drugs, principally hydrallazine or prazosin.
Only 12 patients out of 133 showed absolutely no response at all, and it seemed from this small series that atenolol was marginally more effective than propranolol and in patients prone to bronchospasm was at least the equal of practolol. One of the most useful characteristics of beta blockers as a whole is their relative freedom from adverse effects, and a great many publications have testified to this advantage over the older remedies, and in our experience it is true both of propranolol and of atenolol that even large doses are well tolerated. Both atenolol and propranolol have an acceptable profile of adverse effects. With propranolol, out of 390 patients over ten years less than 10% have had to withdraw for prohibitive adverse effects, and of that 10% quite a number suffered from bronchospasm, and peripheral vascular disease who should not in retrospect be treated with beta blockers anyway. Atenolol presents an even better picture, because the people with bronchospasm are less vulnerable, and it was not used so readily in people with peripheral vascular disease.
The dose-limiting side effects with both drugs were at a very acceptable level. Of the tolerable side effects, cold extremities and fatigue are the ones that most often disturb the physicians, but it is rare to have to stop either propranolol or atenolol because of these symptoms.
The number of patient visits over the whole of this long period of time was noted and the number of times that a particular complaint was made was expressed as a percentage of the number of visits. Three categories were identified: never, sporadic (i.e. complained of at up to 40% of the visits), and frequent (40% or over) (Fig 2) (Zacharias et al. 1976) trasted with propranolol (Fig 3) there is not a great deal of difference, but there is a distinct increase in the frequency of fatigue in the large doses of propranolol. As far as cold extremities are concerned (Fig 4) there is the same sort of problem, fairly frequent, but not really very troublesome with atenolol. With propranolol there is not a great deal of difference, with perhaps a slight increase at the larger doses. Vivid dreams are much less frequent with atenolol because it does not get into the brain to any great extent, compared with propranolol, where the frequency is much greater.
In summary it can be said that atenolol has fulfilled the expectations of its creators in quite a remarkable way. From our own experience it is safe, at least over a period of four years, but we must go on looking at it for a very much longer time. The practolol situation has instilled an element of caution and atenolol will have to be looked at in the largest possible number of patients for the iongest possible period of time, and the longer it is looked at the safer it will be. In these inflationary times, when the cost of developing new drugs is greater than ever, and the time of development is longer than ever, and the safety requirements with licensing authorities are more stringent than ever, it is not surprising that atenolol is an expensive drug, but we must remember that it is no more expensive than the new generation of drugs is going to be. Its ease of administration and freedom from adverse effects should make it acceptable to patients and doctors, and one important thing that its creators did not realize, its small dose range, unlike so many other beta blockers, makes it acceptable to. the taxpayer.
